The FDA has approved abemaciclib for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer that has progressed after failure of initial therapy.
A case study from the University of Colorado suggests that traditional gene testing for NSCLC patients may not be sufficient for detecting potential oncogenic drivers.
The phase III ALCYONE study showed that daratumumab in combination with bortezomib, melphalan, and prednisone is a viable front-line option for myeloma patients who are not candidates for ASCT.
Circulating tumor cells isolated from early stages of lung cancer may be predictive of poor prognosis and could potentially be predictive biomarkers of disease recurrence.
Researchers have discovered a three-drug combo that may combat acute lymphoblastic leukemia by shutting down the production of nucleotides that activate a DNA replication stress response.
Using a CRISPR gene editing technique, researchers have identified dozens of new genes that create T-cell resistant cancer.
Researchers at St. Jude Children’s Research Hospital have discovered a vulnerability that may easily translate into new targeted drug therapies that block heme biosynthesis, killing leukemic cells.
A new study has shown that it may now be possible to predict survival outcomes and patients’ response to chemotherapy based on the molecular classification of four distinct subtypes of gastric cancer.
ASCO is issuing a new clinical practice guideline that clarifies the role of immunotherapy in the treatment of patients with advanced non–small-cell lung cancer.
Natural killer cells derived from donated umbilical cords could be modified to seek and destroy some types of leukemia and lymphoma.